CVD Risk Stratification in Clinical Practice: SCORE2, GRACE, TIMI, and CHA₂DS₂-VASc Explained

Why risk stratification matters in daily cardiology practice

Every cardiologist uses risk scores — but not always systematically. Risk calculators are often used reactively (when filling out an insurance form or justifying a treatment decision) rather than prospectively (to drive the treatment decision in the first place). Used correctly, validated risk scores improve the consistency of clinical decision-making, facilitate patient communication, and create an auditable trail for treatment choices.

This guide covers the four scores most commonly used in outpatient cardiology in Egypt: SCORE2, GRACE, TIMI, and CHA₂DS₂-VASc.

SCORE2 — Primary prevention in stable patients

What it is: SCORE2 (Systematic COronary Risk Evaluation 2) is the European Society of Cardiology's primary prevention risk calculator, updated in 2021. It estimates the 10-year risk of fatal or non-fatal cardiovascular events (heart attack, stroke, cardiovascular death) in people aged 40–69 without established cardiovascular disease. Inputs: Age, sex, smoking status, systolic blood pressure, total cholesterol, and HDL cholesterol. Risk categories:

• Low risk: < 5% at 10 years
• Moderate risk: 5–10%
• High risk: 10–20%
• Very high risk: ≥ 20%

Use SCORE2 for: Any patient aged 40–69 without established CVD who presents for cardiovascular risk assessment, hypertension follow-up, or as part of a health screen. Treatment thresholds for statin initiation and blood pressure targets are defined by SCORE2 category in the 2021 ESC guidelines. SCORE2-OP: A variant of SCORE2 for patients aged 70 and over, which uses different risk thresholds because absolute risk is higher in this age group and the treatment-benefit calculation differs. Egypt calibration: SCORE2 uses region-specific calibration. Egypt falls in the High-Risk country category — use the High-Risk region tables, not the Low-Risk or Moderate-Risk tables.

GRACE 2.0 — Acute Coronary Syndromes

What it is: The GRACE (Global Registry of Acute Coronary Events) score estimates in-hospital mortality risk and 6-month mortality after ACS — STEMI, NSTEMI, or unstable angina. Inputs (GRACE 2.0): Age, heart rate at presentation, systolic BP at presentation, serum creatinine, cardiac arrest at admission, ST-segment deviation, elevated troponin/cardiac enzymes, and Killip class. Risk categories for 6-month mortality:

• Low risk: < 3%
• Intermediate risk: 3–8%
• High risk: > 8%

Clinical application: GRACE score drives the urgency of invasive strategy in NSTEMI/UA. High GRACE score (> 140 on the original GRACE scale) indicates benefit from early invasive strategy within 24 hours. Intermediate GRACE score indicates invasive strategy within 72 hours. Low GRACE score may be managed conservatively with watchful waiting. Key pitfall: GRACE is not appropriate for primary prevention — it is an in-hospital or immediate post-ACS tool. Do not use it for stable outpatients.

TIMI — Risk scores for ACS management

TIMI STEMI score

Predicts 30-day mortality after STEMI. Inputs: age, anterior ST elevation, history of diabetes/hypertension/angina, systolic BP < 100, heart rate > 100, Killip class II–IV, weight < 67 kg, anterior ST elevation, time to treatment > 4 hours.

Use to: Communicate mortality risk to the family and team. High TIMI STEMI scores identify patients who benefit most from adjunctive therapies.

TIMI NSTEMI/UA score

Predicts 14-day risk of death, MI, or urgent revascularisation in NSTEMI/unstable angina. Inputs: age ≥ 65, ≥ 3 CAD risk factors, prior coronary stenosis ≥ 50%, ST deviation, ≥ 2 angina events in prior 24 hours, aspirin use in prior 7 days, elevated serum cardiac markers.

Score 0–2: Low risk. Score 3–4: Intermediate. Score 5–7: High risk. High TIMI score identifies patients who benefit from early invasive strategy and GP IIb/IIIa inhibitors.

CHA₂DS₂-VASc — Stroke risk in atrial fibrillation

What it is: The most widely used clinical decision tool for stroke risk stratification in non-valvular atrial fibrillation. Determines whether anticoagulation is indicated. Scoring:

• C — Congestive heart failure / LV dysfunction: 1 point
• H — Hypertension: 1 point
• A — Age ≥ 75: 2 points
• D — Diabetes mellitus: 1 point
• S — Prior Stroke / TIA / thromboembolism: 2 points
• V — Vascular disease (MI, PAD, aortic plaque): 1 point
• A — Age 65–74: 1 point
• Sc — Sex category (Female): 1 point

Maximum score: 9 (men) or 10 (women) Treatment thresholds (ESC 2020 AF guidelines):

• Score 0 in men, 1 in women (female sex category only): No anticoagulation needed
• Score 1 in men, 2 in women: Consider anticoagulation — weigh against bleeding risk (HAS-BLED)
• Score ≥ 2 in men, ≥ 3 in women: Anticoagulation recommended unless absolute contraindication

Important: The female sex point should not be used in isolation to trigger anticoagulation — it modifies risk in the presence of other risk factors but is not an independent indication. Pairing with HAS-BLED: CHA₂DS₂-VASc identifies patients at risk of stroke. HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke history, Bleeding history, Labile INR, Elderly, Drugs/alcohol) identifies patients at risk of anticoagulation-related bleeding. High HAS-BLED (≥ 3) does not contraindicate anticoagulation — it identifies patients who need more careful monitoring and correction of modifiable bleeding risk factors.

The case for trending scores across visits

A single risk score captures a patient's risk at one point in time. Trending scores across visits shows whether your treatment is actually changing cardiovascular risk:

• A patient whose SCORE2 falls from 18% to 9% over 18 months of statin and antihypertensive therapy has achieved a clinically meaningful risk reduction
• A patient whose CHA₂DS₂-VASc rises from 2 to 4 after a stroke has crossed a threshold that unambiguously mandates anticoagulation

In Clinit, every risk calculation is saved to the patient record with the date, the inputs used, and the result. The dashboard shows SCORE2, CHA₂DS₂-VASc, and recent BP/lipid trends side by side on the cardiology overview screen.